185 related articles for article (PubMed ID: 19366276)
1. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Zhong ZM; Chen JT
Clin Drug Investig; 2009; 29(5):349-57. PubMed ID: 19366276
[TBL] [Abstract][Full Text] [Related]
2. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Katayama K; Matsuno T
Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
[TBL] [Abstract][Full Text] [Related]
3. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
4. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
[TBL] [Abstract][Full Text] [Related]
5. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Hochberg MC
Curr Osteoporos Rep; 2008 Sep; 6(3):89-94. PubMed ID: 18752769
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
7. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Bobba R; Adachi JD
Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178
[TBL] [Abstract][Full Text] [Related]
8. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
9. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Iwamoto J; Matsumoto H; Takeda T
Curr Med Res Opin; 2008 May; 24(5):1379-84. PubMed ID: 18384711
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
13. Effect of osteoporosis treatment on mortality: a meta-analysis.
Bolland MJ; Grey AB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2010 Mar; 95(3):1174-81. PubMed ID: 20080842
[TBL] [Abstract][Full Text] [Related]
14. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Davey DA
S Afr Med J; 2012 Mar; 102(5):285-8. PubMed ID: 22554331
[TBL] [Abstract][Full Text] [Related]
16. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L
BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis: which current treatments reduce fracture risk?
Baran DT
Cleve Clin J Med; 2000 Oct; 67(10):701-3. PubMed ID: 11060956
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
[TBL] [Abstract][Full Text] [Related]
19. [Risedronate for treatment of osteoporosis].
Hagino H
Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Boonen S; Klemes AB; Zhou X; Lindsay R
J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
